Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands.
Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Oct 15;1247:124308. doi: 10.1016/j.jchromb.2024.124308. Epub 2024 Sep 12.
A selective and sensitive liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method was developed and validated for simultaneous quantitation of a cassette of 8 drugs, including docetaxel, erlotinib, loperamide, riluzole, vemurafenib, verapamil, elacridar and tariquidar. Stable isotopically labeled compounds were available for use as internal standards for all compounds, except for tariquidar for which we used elacridar-d4. Sample pre-treatment involved liquid-liquid extraction using tert-butyl-methyl ether as this resulted in good recovery and low ion suppression. Chromatographic separation was achieved using a Zorbax Extend C18 analytical column and a linear gradient from 20 % to 95 % methanol in 0.1 % (v/v) formic acid in water. MS/MS detection using multiple reaction monitoring was done in positive ionization mode. We validated this assay for human and mouse plasma and mouse brain homogenates. The calibration curves were linear over a range 1-200 nM for each drug in the mix, except for tariquidar probably due to the lack of a stable isotope labeled analog. The intra-day and inter-day accuracies were within the 85-115 % range for all compounds at low, medium and high concentrations in the three different matrices. Similarly, the precision for all compounds at three different concentration levels ranged below 15 %, with the exception of tariquidar in mouse plasma and brain homogenate and riluzole in brain homogenate. Pilot studies have confirmed that the method is suitable for the analysis of mouse plasma samples and brain homogenates following cassette dosing of this mixture in mice.
建立并验证了一种选择性和灵敏的液相色谱串联质谱(LC-MS/MS)方法,用于同时定量分析 8 种药物的组合,包括多西他赛、厄洛替尼、洛哌丁胺、利鲁唑、维莫非尼、维拉帕米、埃拉西达和他利奎达。除了使用埃拉西达-d4 作为内部标准外,所有化合物都有稳定同位素标记的化合物可供使用。样品预处理涉及使用叔丁基-甲基醚进行液液萃取,因为这可以获得良好的回收率和低离子抑制。使用 Zorbax Extend C18 分析柱和在水中含有 0.1%(v/v)甲酸的 20%-95%甲醇的线性梯度实现色谱分离。使用正离子化模式进行 MS/MS 检测,采用多反应监测。我们对人血浆、小鼠血浆和小鼠脑匀浆验证了该方法。除了他利奎达可能由于缺乏稳定同位素标记的类似物外,在混合药物中每个药物的 1-200 nM 范围内,校准曲线均呈线性。在三种不同基质中的低、中和高浓度下,所有化合物的日内和日间准确度均在 85-115%范围内。同样,所有化合物在三个不同浓度水平的精密度均低于 15%,除了小鼠血浆和脑匀浆中的他利奎达以及脑匀浆中的利鲁唑。初步研究证实,该方法适用于在小鼠中组合给予该混合物后分析小鼠血浆样品和脑匀浆。